The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 Under Fed Condition in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03738449
• Other study ID #: 184BE18014
• Status: Completed
• Phase: Phase 1
• Start date: January 8, 2019
• Est. completion date: January 24, 2019

Study information

• Verified date: February 2019
• Source: Chong Kun Dang Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to evaluate the pharmacokinetics and safety/tolerability after oral administration of CKD-387 and D484 under fed condition in healthy adults.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: January 24, 2019
• Est. primary completion date: January 18, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adults aged 19 to 55 years

2. Females must be menopause or surgical infertility

3. Signed informed consent form

4. Other inclusion criteria, as defined in the protocol

Exclusion Criteria:

1. History of clinically significant hepatic, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder

2. Clinical laboratory test values are outside the accepted normal range at Screening

• aspartate aminotransferase(AST), alanine aminotransferase(ALT) > 1.25 times the upper limit of the normal range

• Total Bilirubin > 1.5 times the upper limit of the normal range

• creatine phosphokinase(CPK) > 1.5 times the upper limit of the normal range

• estimated Glomerular Filtration Rate(eGFR, MDRD* formula) < 60 mL/min/1.73m2 (*MDRD: Modification of Diet in Renal Disease)

• Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis

• systolic blood pressure(SBP) = 150 mmHg or < 90 mmHg, diastolic blood pressure(DBP) > 100 mmHg or < 50 mmHg

3. Subject who smoke heavily or drink caffeine or alcohol continuously and who cannot discontinue smoking, caffeine or alcohol intake during hospitalization

4. Participated in a clinical trial within 90 days prior to 1st IP dosing

5. Not eligible to participate for the study at the discretion of Investigator

6. Other exclusive inclusion criteria, as defined in the protocol

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• CKD-387
Test drug
• D484
reference drug

Locations

Country	Name	City	State
Korea, Republic of	Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum plasma concentration of Metformin	Cmax of Metformin	0 hour ~ 48 hour after drug administration
Primary	Area under the plasma concentration of Metformin-time curve from time zero to time of last measurable concentration	AUClast of Metformin	0 hour ~ 48 hour after drug administration
Secondary	Area under the plasma concentration of Metformin-time curve from time zero to infinity	AUCinf of Metformin	0 hour ~ 48 hour after drug administration
Secondary	Time to reach maximum (peak) plasma concentration of Metformin following drug administration	Tmax of Metformin	0 hour ~ 48 hour after drug administration
Secondary	Half-life of Metformin	t1/2 of Metformin	0 hour ~ 48 hour after drug administration
Secondary	Apparent clearance of Metformin	CL/F of Metformin	0 hour ~ 48 hour after drug administration
Secondary	Apparent volume of distribution of Metformin	Vd/F of Metformin	0 hour ~ 48 hour after drug administration